Volume 11 Issue 284
Published - 14:00 UTC 08:00 EST 27-Oct-2009 
Next Update - 14:00 UC 08:00 EST 28-Oct-2009

Editor: Susan K. Boyer, RN
Vidyya.
All rights reserved.




  

 




Do drug therapies raise risk of bladder cancer?

(27 October 2009: VIDYYA MEDICAL NEWS SERVICE) -- In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

The findings, from a population-based, case-control study in New Hampshire, appear in the September 2009 issue of the British Journal of Cancer, with Dartmouth Medical School student Karl Dietrich as first author, with DMS professors Alan R. Schned, M.D., and John A. Heaney, M.D., as co-authors, and with Karagas, a professor of community and family medicine at DMS, as principal investigator. The report examines the long-term use of glucocorticoids by 786 bladder-cancer patients and by 1,083 control subjects.

Doctors commonly prescribe a combination of cytotoxic drugs and glucocorticoids as immunosuppressive therapy to help recipients of transplants avoid rejection of their new organs, and patients with rheumatoid arthritis, asthma, and other conditions often take glucocorticoids. Previous research, in some of which Karagas participated, has shown associations between such drug therapies and higher risk of skin cancer and lymphoma. A similar risk for bladder cancer, the new report says, "might indicate the need for closer monitoring of individuals who regularly take glucocorticoids."

http://www.nature.com/bjc/journal/v101/n8/full/6605314a.html

Return to Vidyya Medical News Service for 27 October 2009

© Vidyya. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@vidyya.com with the word subscribe in the subject field.